Abstract
Background
While autologous fat grafting of the face is considered a generally safe procedure, severe complications such as arterial embolism (AE) have been reported.
Objective
To summarize data on injection-related visual compromise, stroke, and death caused by arterial embolism after facial fat transplantation.
Materials and Methods
Plastic surgery societies were contacted for reports on AE after autologous facial fat injection. In addition, a systematic literature review was performed. Data extracted included study design, injection site/technique, symptoms, management, outcome, and etiology.
Results
61 patients with a mean age of 33.56 ± 11.45 years were reported. Injections targeted the glabella or multiple facial regions (both n = 16/61, 26.2%) most commonly, followed by injections in the temples (n = 10/61, 16.4%) and the forehead (n = 9/61, 14.8%). The mean volume injected was 21.5 ± 21.5 ml. Visual symptoms were described most frequently (n = 24/58, 41.4%) followed by neurological symptoms (n = 20/58, 34.5%), or both (n = 13/58, 22.4%). Ophthalmic artery (OA, n = 26/60, 43.3%), anterior or middle cerebral artery (CA, n = 11/60, 18.3%) or both (n = 14/60, 23.3%) were most frequently occluded. Outcome analysis revealed permanent vision loss in all patients with OA occlusion (n = 26/26, 100%), neurological impairment in most patients with CA occlusion (n = 8/10, 80%), and vision loss in most patients suffering from both OA and CA occlusion (n = 7/11, 63.6%). Six patients died following embolisms.
Conclusions
AE causes severe complications such as blindness, stroke, and death. Due to a lack of high-quality data, no evidence-based treatment algorithms exist. To increase patient safety, a database collecting cases and complications should be established.
Level of Evidence III
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
A plethora of articles has been published focusing on complications after minimally invasive procedures for rejuvenation of the face, amelioration of facial wrinkles, contouring and augmentation of facial features [1,2,3,4]. One of the most devastating complications, i.e., injection-related visual compromise (IRVC) has gained attention, due to increasing reports of blindness after soft-tissue filler injections [5, 6]. The increase in IRVCs can be linked to the constant rise of procedures in the facial region over the past decade. This is accompanied by an improved understanding of the underlying pathophysiology [7]. Retrograde intravascular administration of a bolus of soft-tissue filler can cause occlusion of the ophthalmic/central retinal/posterior ciliary arteries, irrespective of the physicochemical properties of the injected material. Several treatment algorithms have been established, providing protocols for the management of these complications [8, 9]. Exemplary, these protocols provide specific recommendations including retrobulbar hyaluronidase injections and pharmacotherapy in case of an IRVC caused by a hyaluronic acid (HA)-based filler.
As HA-based fillers are categorized as medical devices, strict regulations and rigorous post market surveillance are imposed by respective authorities, e.g., the Food and Drug Administration (FDA) in the USA or the European Medicines Agency (EMA) in Europe. Databases such as the Manufacturer and User Facility Device Experience (MAUDE) database collect post-marketing safety surveillance data of (serious) adverse events for FDA-approved medical devices [10]. While most studies focus on arterial embolism (AE) after HA-based soft-tissue filler injections, there are also reports describing cases of blindness and even stroke after autologous fat injections in the face. According to the International Society of Aesthetic Plastic Surgeons (ISAPS), autologous fat grafting of the face was ranked as the 7 most common aesthetic surgical procedure worldwide with a total of 589,494 procedures performed [11]. Yet, as autologous fat is not classified as a medical device or drug, pharmacovigilance measures including databases on adverse events and complications of this procedure are necessary. In contrary to HA injections, the absence of effective antidotes to arterial fat embolisms results in a lack of specific recommendations and treatment strategies. As the autologous fat transfer is increasingly being performed by healthcare providers without specific training in plastic and aesthetic surgery, there is need for increasing awareness regarding AE after autologous fat injection of the face.
This systematic literature review aims to summarize current data on the topic and analyze the etiology, facial regions injected, injection techniques, and management of cases where visual and neurological complications occurred. In addition, the aim was to investigate whether and how complications after autologous fat injections in the face are recorded and documented, on both national and international level.
Materials and Methods
A total of 16 national and international plastic surgical societies were contacted via publicly available contact details (i.e., contact email addresses provided on the respective websites) and questioned whether a database monitoring complications following autologous fat injection of the face exist. (Table 1) In addition, a systematic literature review was performed according to the Preferred Reporting Systems for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [12]. PubMed and Embase databases were searched for manuscripts on AE after autologous facial fat grafting. The following search strategies were utilized:
-
1.
PubMed: (((((autologous fat transplantation[MeSH Terms]) OR (fat injection[MeSH Terms])) OR (fat grafting[MeSH Terms])) AND (face[MeSH Terms])) OR (facial[MeSH Terms])) AND (embolism[MeSH Terms]), Most Recent,, “(((((( ““autolog”” [All Fields] OR ““autologous”” [All Fields] OR ““autologic”” [All Fields] OR ““autological”” [All Fields] OR ““autologous”” [All Fields] OR ““autologously”” [All Fields]) AND ““fat”” [All Fields]) AND ““transplantation”” [MeSH Terms]) OR (““fat”” [All Fields] AND ““injections”” [MeSH Terms]) OR (““fat”” [All Fields] AND ““transplantation”” [MeSH Terms])) AND ““face””[MeSH Terms]) OR ““face”” [MeSH Terms]) AND ““embolism”” [MeSH Terms]”
-
2.
Embase: ((fat injection or fat transplantation or fat grafting or lipofilling) and (face or facial) and (blindness or vision loss or visual impairment or embolism))af.
All cases of AE after injection of autologous fat in the face published in the English language were included, irrespective of patient age, gender, location, and technique of injection. Exclusion criteria were studies not performed in humans, injection of other fillers (i.e., hyaluronic acid, calcium hydroxyl apatite), or injection of fat outside of the face. Primary literature with original research articles was included, in addition to case reports and editorials, while secondary sources such as review articles and meta-analyses were screened, and reference lists were hand-searched to identify studies that may have been missed by the systematic literature search (snowballing). The literature search was completed on January 1st, 2023. Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) was utilized for the removal of duplicates, title and abstract screening, and full-text review. (Fig. 1) Two authors (N.M., C.K.) independently screened the titles and the abstracts for eligibility which were identified in the electronic database search.
Data extraction
Data extracted included study title, first author, date, country, study design, gender, age, injection site, injection technique, volume injected, symptoms, the onset of symptoms, management, outcome, etiology, and follow-up time.
To enable statistical analysis, symptoms were categorized into neurological symptoms (including loss of consciousness, seizure, change of mental status, aphasia, paresthesia, paresis, headaches), visual symptoms (including vision loss, blindness, visual impairment, ocular pain), and cardiopulmonary symptoms (including respiratory, or cardiac decompensation, loss of oxygen saturation, dyspnea). Duration to the first onset of symptoms was categorized into the following ranges: immediate onset to 1 h post-injection, 2–23 h post-injection, and ≥ 24 h post-injection. Outcomes were categorized into vision loss, neurological impairment, and death.
Etiology was analyzed in cases where it was clearly described and identified. Categorization was performed as ophthalmic artery occlusion (OAO, including ophthalmic artery, central retinal artery, ciliary artery), cerebral artery occlusion (CAO, including anterior, middle, posterior cerebral artery), or both, pulmonary embolism, unclear or other.
Statistical analysis
Data are presented as means with standard deviation, or as absolute and relative frequencies unless stated otherwise. Data were tabulated using Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA). Descriptive statistics were performed using SPSS Statistics 28 (IBM, Armonk, NY, USA).
Results
The follow-up and response rate of national and international plastic surgical societies contacted were low (Table 1). There were no reports on the existence of an established database monitoring complications following autologous fat grafting of the face, and therefore, no cases were obtained. Contrary, the systematic literature review yielded a total of 61 cases (n = 53/61, 86.9% females; n = 7/61, 11.5% males; n = 1/61, 1.6% transgender) with a mean age of 33.56 ± 11.45 (range 18–66) in 39 manuscripts (Table 2). The detailed citation attrition diagram can be found in Fig. 1. Most articles reported cases in China (n = 14/39, 35.9%) and South Korea (n = 12/39, 30.8%); however, reports were also found in other Asian countries, the US, Europe, Australia, and New Zealand. Most identified studies were case reports (n = 21/61, 53.8%), followed by case series (n = 9/61, 23.1%), letters to the editor (n = 4/61, 10.3%), case reports with reviews (n = 4/61, 10.3%), or correspondences (n = 1/61, 2.6%). The mean follow-up time was 166.73 ± 207.96 (range 3–730) days.
Injection
While injections were performed in all facial areas, a detailed analysis of the reported cases revealed that most frequently injections targeted the glabella region only or multiple facial regions (both n = 16/61, 26.2%), followed by injections in the temples (n = 10/61, 16.4%), the forehead (n = 9/61, 14.8%), the midface (including nasolabial fold and cheek, n = 5/61, 8.2%), the periorbital region (n = 3/61, 4.9%), and the nose (n = 2/61, 3.3%). The exact injection technique was reported infrequently. In those reports that included the injection technique, n = 11/17 (64.7%) reported the use of a needle, while n = 6/17 (35.3%) reported the use of a cannula during the injection. The mean total volume of injection (reported in n = 20 reports) was 21.5 ± 21.5 ml of autologous fat (range 0.5–70 ml).
Onset of symptoms and outcome
The onset of symptoms ranged between immediate onset and 1 week postoperative. Most frequently, symptoms occurred immediately to 1 h post-injection (n = 33/50, 66.0%), followed by onset between 2 and 23 h post-injection (n = 12/50, 24.0%) and ≥ 24 h post-injection (n = 5/50, 10.0%). Visual symptoms were described most frequently (n = 24/58, 41.4%) followed by neurological symptoms (n = 20/58, 34.5%), or both visual and neurological symptoms (n = 13/58, 22.4%). Analysis of outcomes revealed permanent vision loss (n = 32/54, 59.3%), neurological impairment (n = 12/54, 22.2%), both neurological and visual impairment (n = 4/54, 7.4%), and death (n = 6/54, 11.1%).
Management
Management of symptoms highly depended on the individual documented case and included conservative treatment (i.e., ocular massage), pharmacological (i.e., nitroglycerin, aspirin, prednisone, mannitol), minimally invasive (i.e., embolectomy), as well as operative interventions (i.e., decompressive hemicraniectomy).
Etiology
Etiology was analyzed revealing OAO (n = 26/60, 43.3%), CAO (n = 11/60, 18.3%), or both (n = 14/60, 23.3%) to be the most frequent causes for the symptoms and outcomes described. Unclear/other causes and pulmonary embolism were reported in n = 8/60 (13.3%) and n = 1/60 (1.7%), respectively. Patients were stratified into three different groups, according to the etiology: OAO, CAO, and both OAO and CAO. The injection site, symptoms, the duration of the first symptoms, and outcomes were analyzed for each group (see Figs. 2, 3, 4 and 5). OAO occurred most frequently after injections into the glabella, forehead, and periorbital region (n = 6/26, 23.1% each), and CAO after injections into the temples (n = 5/11, 45.5%) and both OAO and CAO combined after injections into the glabella region (n = 5/14, 35.7%). Visual symptoms were experienced most frequently by patients within the OAO group (n = 20/26, 76.9%); neurological symptoms were reported most frequently by patients in the CAO group (n = 10/11, 90.9%) and a combination of visual and neurological symptoms by the group suffering from both OAO and CAO (n = 7/13, 53.8%). The most frequent onset of symptoms ranged between immediate-1h post-intervention in all groups. Outcome analysis revealed vision loss in all patients with OAO (n = 26/26, 100%), neurological impairment in most patients with CAO (n = 8/10, 80%), and vision loss in most patients suffering from both OAO and CAO (n = 7/11, 63.6%). Deaths were not associated primarily with a specific etiology, or injection site (Table 3).
Discussion
This systematic review revealed a paucity of high-quality data on AE after facial autologous fat injections. Incidence, clinical manifestation, recommendations and or algorithms for treatment, and advice regarding the prevention of arterial embolization are based on case reports, case series, letters, and correspondences. Contacting national and international societies revealed no centralized and standardized monitoring of adverse events after autologous fat grafting of the face. Consequences of AE after autologous fat injection are, however, undeniable. The data retrieved by the systematic literature review revealed severe visual and neurological deficits which most commonly occur within a few seconds to minutes after intraarterial injection. These include vision loss, stroke-related symptoms such as hemiplegia, and even death, depending on the location of the fat embolus and the artery occluded. Hence, an understanding of the pathomechanisms, the symptoms, the potential etiology, and outcomes is essential for surgeons to recognize, manage, and prevent these complications accordingly.
Vascular anatomy and pathophysiology
The face is supplied by the internal and external carotid artery (ICA, ECA), which give off major branches to the upper, middle, and lower face [52]. These branches form a vast anastomotic network between each other and between both hemifaces. Retrograde injection of autologous fat into the ICA system can cause severe complications, depending on the exact location of the vascular occlusion. Two mechanisms are possible, i.e., direct intravasation and retrograde bolus advancement of fat into branches of the ICA system (such as the dorsal nasal, the supratrochlear, or supraorbital artery in the glabella region) or by injecting into the ECA system with consecutive embolus occlusion of the internal system via one of the many anastomoses between external and internal carotid artery (i.e., supraorbital arcade which marks anastomoses of the superficial temporal, transverse facial, and zygomatic orbital, as well as supraorbital/supratrochlear arteries) [7, 53, 54]. Hence, prior to autologous fat grafting in the face, surgeons must be aware of the three-dimensional course of vessels, to adapt the respective tissue layer, depth, and direction of injection.
The glabella, forehead, and temple region were among the sites most frequently affected by injection-related AEs. In addition, periorbital and nasolabial injections belong to the most popular facial regions in which autologous fat injection is being performed. Hence, the arterial vasculature of these facial regions shall be further highlighted.
The glabella region is likely to be most prone to IRVC and/or stroke, as terminal branches of the ophthalmic artery (ICA vascular network) provide the vascular supply to this region [5, 6]. The supratrochlear, the supraorbital, and the dorsal nasal artery branch off the ophthalmic artery and exit the bony skull via distinct foramina/notches. The supraorbital and supratrochlear arteries emerge from the supraciliary arch of the frontal bone and course cranially toward the forehead. In the glabella and lower forehead, they are located in a deep layer beneath the frontalis muscle. During their course cranially, branches of these arteries can change plane to travel more superficially, above the frontalis muscle, at approximately 1.5–2.5 cm superior to the supraorbital rim [55, 56]. However, it needs to be pointed out that the supratrochlear, as well as the supraorbital artery often branch off into a superficial and a deep branch. The superficial branch might emerge to the superficial layer much more caudal, than the deep branch. The dorsal nasal artery runs inferiorly toward the nose 4–5 mm lateral to the midline [57]. In most cases, it can be found superficially, within the subcutaneous tissue on top of the nasalis muscle [58]. A rich anastomotic network with the ECA can be found, as it has multiple anastomoses with the angular artery and the lateral nasal artery, the palpebral arteries, the infraorbital artery, and the superior labial artery [59, 60].
The superficial and deep temporal arteries provide vascular supply to the temple region. The superficial temporal artery branches off the ECA at the anterior border of the tragus and courses obliquely toward the temporal crest. It is located within the superficial temporal fascia [52, 61, 62]. The deep temporal arteries branch off the maxillary artery, which itself is a branch of the ECA. The anterior and posterior deep temporal artery are located beneath the temporalis muscle, approximately 2.5 cm lateral to the lateral orbital rim; however, this landmark should not be considered as marking a safe zone, as perforators of the anterior deep temporal artery might course closer to the lateral orbital rim [63].
Recent data revealed up to five anastomotic pathways between the ICA and ECA in the upper face (including temples, forehead, and the periorbital region). These are formed via the frontal branch of the superficial temporal artery, branches of the transverse facial artery, and the zygomatic-orbital artery with terminal branches of the ICA both deep to and superficial to the superficial fascia (i.e., the frontalis muscle in the forehead, the superficial temporal fascia in the temple, and the orbicularis oculi muscle in the periorbital region) [54]. These findings provide an explanatory model as to why IRVC and stroke can occur after injections of the temple, the zygomatic arch, and the lateral periorbital region.
Management
No standardized guidelines for the management of AE after autologous fat grafting of the face exist. Unlike HA injections which can be dissolved using hyaluronidase, there is no agent for fat emboli resolution of comparable effect. Management of AE after facial fat grafting, therefore, consists of conservative therapy, pharmacotherapy, minimally invasive interventions, and operative procedures. Most cases of vision loss in patients with OAO were managed using symptomatic treatment via digital ocular massage, eye drops, aspirin, prednisone, and nitroglycerin. Unfortunately, treatment modality had no effect on the outcome as all patients with OAO suffered from irreversible vision loss. Occlusion of the ophthalmic, central retinal, or ciliary arteries causes ischemia of the retina. The retinal cells are especially susceptible to hypoxia and vascular occlusion thus leading to vision loss within minutes rather than hours [64]. To date, no effective intervention to reverse retinal hypoxia and cell degradation exists. Emergent thrombolytic therapy is being explored; however, further randomized clinical trials are warranted [65]. It needs to be pointed out that treatment approaches aiming to improve retinal perfusion (i.e., carbogen, acetazolamide, topical beta-blockers, ocular massage, and anterior chamber paracentesis) in the setting of a central retinal artery occlusion caused by a stroke lack efficacy so far, which furthermore highlights the unfortunate therapeutic situation for now [66,67,68].
Patients with neurological impairment and stroke after CAO treatment of choice was mechanical embolectomy and/or decompressive hemicraniectomy in combination with systemic corticosteroid treatment and/or thrombolysis in most cases. However, once more the outcome was highly unfavorable despite these treatment efforts. Due to the limited effectiveness of treatment of vascular occlusion, preventive measures appear to be the more dominant solution within the conceptual management of this complication entity.
Prevention
Several measures to prevent vascular occlusion after soft-tissue filler injection have been defined [69,70,71,72]. General measures such as slow retrograde injections of small aliquots, pre-injection aspiration, low injection pressure, and cannula use are advisable. However, these recommendations are often eminence, rather than evidence-based, and the applicability of these preventive measures for fat grafting can be limited. For HA-based soft-tissue filler injections, boluses smaller than 0.1cc are often recommended to avoid IRVC, as the diameter of the ophthalmic artery was reported to range between 0.04 and 0.12 ml [73]. Injection of such small fat boluses may be considered neither practical nor effective, which limits this preventive measure in the context of fat grafting. With the emergence of micro-, nano–fat and lipoconcentrate [74], it needs to be assessed whether different reconstitutions of fat do possess different thrombogenic properties and carry eventually different risks of arterial occlusion.
Previously published data revealed that the force required for arterial penetration increases with increasing needle/cannula size, highlighting that larger needles/cannulas are safer, compared to ones with a smaller diameter [75]. At the same time, cannulas are considered safer than needles [76] as the force required for vascular wall penetration is significantly increased when using blunt-tip cannulas, when compared to needles [75]. In line with this, and although reporting was limited to merely a few cases, the incidence of AE after fat injection was more frequently observed using needles than cannulas in this systematic review. Schiraldi et al. summarized important safety measures based on their systematic review of complications after facial fat grafting including slow, retrograde injection of small aliquots using large diameter cannulas (i.e., 18 Gauge or larger) and small (1ml) syringes [77]. Foremost, it is the opinion of the authors of this manuscript that anatomical knowledge and understanding of the underlying vasculature and its 3-dimensional course are paramount to increase the safety prior to performing these procedures. As for hyaluronic acid injections, the feasibility of ultrasound guided injection of fat needs to be elaborated in the future [78, 79].
Reporting and Monitoring of Complications
To the knowledge of the authors, and after contacting several plastic surgery societies, no standardized and centralized database collecting complications after facial augmentation using autologous fat exists. Given the low incidence of AE after autologous fat injection—preventing the conduct of meaningful clinical trials—paired with the severity of outcomes, there is a strong need for documentation of this complication cluster to create evidence-based prevention/management algorithms. Importantly, data acquisition should be governed by a centrally maintained but universally accessible entity and should encompass high resolution data including precise details of the entire periprocedural phase plus sufficient follow-up. Unfortunately, lipografting of the face—like hyaluronic acid injection—can be performed by medical professionals who are not specialized within the field of plastic, reconstructive and aesthetic surgery in some countries. Most cases in literature were reported in China (n = 29/61, 47.5%) and Korea (n = 18/61, 29.5%). Although there is a lack of reliable data to quantify the number of facial fat grafting procedures performed annually in these countries, the demand for aesthetic surgery is known to be high [80]. Recently, reports have uncovered so called ghost-surgeries [81], performed by un- or underqualified practitioners, and while there remains room for speculation, this could provide an explanation for an increase in complications.
Importantly, the patients themselves are often unaware of the qualification of the medical professional treating them, as the term aesthetic or beauty surgeon is often not protected by law and is in many countries not limited to specialized plastic (and aesthetic) surgeons [82, 83]. Thus, there needs to be a change and international harmonization in legislation to prevent complications arising from use of wrong injection technique, plane, and material by unqualified practitioners.
Conclusions
Severe complications such as blindness, stroke, and death can occur due to AE after facial fat grafting. Based on currently available literature, 61 cases were identified, with approximately 600.000 procedures being performed annually [11]. While these complications can therefore be considered rare, exact numbers of incidence cannot be provided due to the limited data available. In addition, there is reason to believe in underreporting of these complications. Due to the severity of these complications, in a supposedly simple procedure such as lipografting of the face, this article wants to sensitize the audience toward them. Presently, the dearth of high-quality data inherently leads to missing evidence-based prevention/treatment algorithms. To increase patient safety and awareness for the severe complications and outcomes associated with AE after facial fat injection, an international database for documentation and surveillance of fat grafting-induced complications is pivotal.
References
Ozturk CN, Li Y, Tung R, Parker L, Piliang MP, Zins JE (2013) Complications following injection of soft-tissue fillers. Aesthet Surg J 33(6):862–877. https://doi.org/10.1177/1090820X13493638
Rzany B, DeLorenzi C (2015) Understanding, avoiding, and managing severe filler complications. Plast Reconstr Surg 136(5 Suppl):196S–203S. https://doi.org/10.1097/PRS.0000000000001760
DeLorenzi C (2013) Complications of injectable fillers, part I. Aesthet Surg J 33(4):561–575. https://doi.org/10.1177/1090820X13484492
DeLorenzi C (2014) Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J 34(4):584–600. https://doi.org/10.1177/1090820X14525035
Beleznay K, Carruthers JD, Humphrey S, Jones D (2015) Avoiding and treating blindness from fillers: a review of the world literature. Dermatol Surg 41(10):1097–1117. https://doi.org/10.1097/DSS.0000000000000486
Beleznay K, Carruthers JDA, Humphrey S, Carruthers A, Jones D (2019) Update on avoiding and treating blindness from fillers: a recent review of the world literature. Aesthet Surg J 39(6):662–674. https://doi.org/10.1093/asj/sjz053
Soares DM (2022) Bridging a century-old problem: the pathophysiology and molecular mechanisms of HA filler-induced vascular occlusion (FIVO)-implications for therapeutic interventions. Molecules 27(17):5398. https://doi.org/10.3390/molecules27175398
Barbarino S, Banker T, Fezza J (2022) Standardized approach to treatment of retinal artery occlusion after intraarterial injection of soft tissue fillers: EYE-CODE. J Am Acad Dermatol 86(5):1102–1108. https://doi.org/10.1016/j.jaad.2020.12.047
Snozzi P, van Loghem JAJ (2018) Complication management following rejuvenation procedures with hyaluronic acid fillers-an algorithm-based approach. Plast Reconstr Surg Glob Open 6(12):e2061
MAUDE: Manufacturer and User Facility Device Experience. Available from: accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM.; Accessed: 09 Dec 2022.
https://www.isaps.org/media/vdpdanke/isaps-global-survey_2021.pdf; Accessed: 21 Mar 2023.
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https://doi.org/10.1136/bmj.n71
Miao J, Sun W, Zhu Z, Yang Z, Xu Y (2021) A massive right hemisphere infarction after autologous fat grafting for facial filling. J Craniofac Surg 32(2):e215–e217. https://doi.org/10.1097/SCS.0000000000006898
Gleeson CM, Lucas S, Langrish CJ, Barlow RJ (2011) Acute fatal fat tissue embolism after autologous fat transfer in a patient with lupus profundus. Dermatol Surg 37(1):111–115. https://doi.org/10.1111/j.1524-4725.2010.01829.x
Yoon SS, Chang DI, Chung KC (2003) Acute fatal stroke immediately following autologous fat injection into the face. Neurology 61(8):1151–1152. https://doi.org/10.1212/wnl.61.8.1151
Kang JH, Park KH, Park JS (2016) Acute mental change and hemiplegia after autologous fat injection. J Cosmet Laser Ther 18(7):413–416. https://doi.org/10.1080/14764172.2016.1197400
Feinendegen DL, Baumgartner RW, Vuadens P et al (1998) Autologous fat injection for soft tissue augmentation in the face: A safe procedure? Aesthet Plast Surg 22(3):163–167. https://doi.org/10.1007/s002669900185
Wang X, Wu M, Zhou X, Liu H, Zhang Y, Wang H (2018) Autologous fat used for facial filling can lead to massive cerebral infarction through middle cerebral artery or facial intracranial branches. J Craniofac Surg 29(5):1341–1343. https://doi.org/10.1097/SCS.0000000000004625
Teimourian B (1988) Blindness following fat injections. Plast Reconstr Surg 82(2):361
Liu C, Cai Z, Zhang L, Zhou M, He L (2021) Case report and literature review: catastrophic embolism following cosmetic injection of autologous fat in the face. Front Med (Lausanne) 8:646657. https://doi.org/10.3389/fmed.2021.646657
Danesh-Meyer HV, Savino PJ, Sergott RC (2001) Case reports and small case series: ocular and cerebral ischemia following facial injection of autologous fat. Arch Ophthalmol 119(5):777–778
Hong JH, Ahn SJ, Woo SJ et al (2014) Central retinal artery occlusion with concomitant ipsilateral cerebral infarction after cosmetic facial injections. J Neurol Sci 346(1–2):310–314. https://doi.org/10.1016/j.jns.2014.08.030
Han S (2006) Cerebral and ocular fat embolism after autologous fat injection into the face: confirmed by magnetic resonance spectroscopy. J Korean Neurol Assoc 24(4):399–401
Huo X, Liu R, Wang Y et al (2018) Cerebral fat embolism as complication of facial fat graft: retrospective analysis of clinical characteristics, treatment, and prognosis. World Neurosurg 120:249–255. https://doi.org/10.1016/j.wneu.2018.08.148
Thaunat O, Thaler F, Loirat P, Decroix JP, Boulin A (2004) Cerebral fat embolism induced by facial fat injection. Plast Reconstr Surg 113(7):2235–2236. https://doi.org/10.1097/01.prs.0000123627.33690.9e
Carle MV, Roe R, Novack R, Boyer DS (2014) Cosmetic facial fillers and severe vision loss. JAMA Ophthalmol. 132(5):637–639. https://doi.org/10.1001/jamaophthalmol.2014.498
Liu L, Yin M, Liu S, Hu M, Zhang B (2020) Facial filler causes stroke after development of cerebral fat embolism. Lancet 395(10222):449. https://doi.org/10.1016/S0140-6736(20)30001-5
Dhooghe NS, Maes S, Depypere B et al (2022) Fat embolism after autologous facial fat grafting. Aesthet Surg J 42(3):231–238. https://doi.org/10.1093/asj/sjab252
Chen Y, Wang W, Li J, Yu Y, Li L, Lu N (2014) Fundus artery occlusion caused by cosmetic facial injections. Chin Med J 127(8):1434–1437
Park SW, Woo SJ, Park KH, Huh JW, Jung C, Kwon OK (2012) Iatrogenic retinal artery occlusion caused by cosmetic facial filler injections. Am J Ophthalmol 154(4):653–662. https://doi.org/10.1016/j.ajo.2012.04.019
Wang DW, Yin YM, Yao YM (2014) Internal and external carotid artery embolism following facial injection of autologous fat. Aesthet Surg J. 34(8):NP83–NP87
Liu H, Wu X, Zhang X, Niu C, Zhu H (2019) Internal carotid artery embolism after autologous fat injection for temporal augmentation. Aesthetic Plast Surg 43(2):383–387. https://doi.org/10.1007/s00266-018-1265-0
Lee KM, Kim EJ, Jahng GH, Chang DI (2012) Magnetic resonance findings in two episodes of repeated cerebral fat embolisms in a patient with autologous fat injection into the face. J Korean Neurosurg Soc 51(5):312–315. https://doi.org/10.3340/jkns.2012.51.5.312
Shen X, Li Q, Zhang H (2016) Massive cerebral infarction following facial fat injection. Aesthet Plast Surg 40(5):801–805. https://doi.org/10.1007/s00266-016-0681-2
Qian H, Ling Y, Zhang M et al (2021) Massive cerebral infarction following facial injection of autologous fat: a case report and review of the literature. Front Hum Neurosci 15:610945. https://doi.org/10.3389/fnhum.2021.610945
Egido JA, Arroyo R, Marcos A, Jimenez-Alfaro I (1993) Middle cerebral artery embolism and unilateral visual loss after autologous fat injection into the glabellar area. Stroke 24(4):615–616. https://doi.org/10.1161/01.str.24.4.615
Hu J, Chen W, Wu Y et al (2011) Middle cerebral artery occlusion following autologous bitemporal fat injection. Neurol India 59(3):474–475. https://doi.org/10.4103/0028-3886.82749
Roshandel D, Soheilian M, Pakravan M, Aghayan S, Peyman GA (2015) Middle cerebral artery, ophthalmic artery, and multibranch retinal vessel occlusion after cosmetic autologous fat transfer to forehead. Ophthalm Surg Lasers Imaging Retina 46(5):593–596. https://doi.org/10.3928/23258160-20150521-15
Lee YJ, Kim HJ, Choi KD, Choi HY (2010) MRI restricted diffusion in optic nerve infarction after autologous fat transplantation. J Neuroophthalmol 30(3):216–218. https://doi.org/10.1097/WNO.0b013e3181c5d147
Szantyr A, Orski M, Marchewka I, Szuta M, Orska M, Zapala J (2017) Ocular complications following autologous fat injections into facial area: case report of a recovery from visual loss after ophthalmic artery occlusion and a review of the literature. Aesthet Plast Surg 41(3):580–584. https://doi.org/10.1007/s00266-017-0805-3
Lee CM, Hong IH, Park SP (2011) Ophthalmic artery obstruction and cerebral infarction following periocular injection of autologous fat. Korean J Ophthalmol 25(5):358–361. https://doi.org/10.3341/kjo.2011.25.5.358
Liu H, Chen D, Zhang J (2020) Ophthalmic artery occlusion after forehead autologous fat injection. Retin Cases Brief Rep 14(3):271–274. https://doi.org/10.1097/ICB.0000000000000694
Xing L, Almeida DR, Belliveau MJ et al (2012) Ophthalmic artery occlusion secondary to fat emboli after cosmetic nasal injection of autologous fat. Retina 32(10):2175–2176. https://doi.org/10.1097/IAE.0b013e31826a6897
Park SJ, Woo SJ, Park KH et al (2011) Partial recovery after intraarterial pharmacomechanical thrombolysis in ophthalmic artery occlusion following nasal autologous fat injection. J Vasc Interv Radiol 22(2):251–254. https://doi.org/10.1016/j.jvir.2010.10.023
Lu L, Xu X, Wang Z, Ye F, Fan X (2013) Retinal and choroidal vascular occlusion after fat injection into the temple area. Circulation 128(16):1797–1798. https://doi.org/10.1161/CIRCULATIONAHA.112.000397
Dreizen NG, Framm L (1989) Sudden unilateral visual loss after autologous fat injection into the glabellar area. Am J Ophthalmol 107(1):85–87. https://doi.org/10.1016/0002-9394(89)90823-4
Park SH, Sun HJ, Choi KS (2008) Sudden unilateral visual loss after autologous fat injection into the nasolabial fold. Clin Ophthalmol 2(3):679–683
Lee DH, Yang HN, Kim JC, Shyn KH (1996) Sudden unilateral visual loss and brain infarction after autologous fat injection into nasolabial groove. Br J Ophthalmol 80(11):1026–1027. https://doi.org/10.1136/bjo.80.11.1026
Hong DK, Seo YJ, Lee JH, Im M (2014) Sudden visual loss and multiple cerebral infarction after autologous fat injection into the glabella. Dermatol Surg 40(4):485–487. https://doi.org/10.1111/dsu.12426
Putthirangsiwong B, Vongsilpavattana V, Leelawongs S, Chanthanaphak E, Tunlayadechanont P, Chokthaweesak W (2022) Superior ophthalmic vein embolism following forehead augmentation with autologous fat injection. Aesthet Plast Surg 46(1):450–455. https://doi.org/10.1007/s00266-021-02414-0
Zhou K, Cai C (2019) The successful mechanical lipectomy treatment of cerebral fat embolism following autologous fat injection. Plast Reconstr Surg Glob Open 7(1):e2091
Cotofana S, Lachman N (2019) Arteries of the face and their relevance for minimally invasive facial procedures: an anatomical review. Plast Reconstr Surg 143(2):416–426. https://doi.org/10.1097/PRS.0000000000005201
Cho KH, Dalla Pozza E, Toth G, Bassiri Gharb B, Zins JE (2019) Pathophysiology study of filler-induced blindness. Aesthet Surg J 39(1):96–106. https://doi.org/10.1093/asj/sjy141
Li ZH, Alfertshofer M, Hong WJ et al (2022) Upper facial anastomoses between the external and internal carotid vascular territories - a 3D computed tomographic investigation. Aesthet Surg J 42(10):1145–1151. https://doi.org/10.1093/asj/sjac060
Cotofana S, Velthuis PJ, Alfertshofer M et al (2021) The change of plane of the supratrochlear and supraorbital arteries in the forehead-an ultrasound-based investigation. Aesthet Surg J. 41(11):NP1589–NP1598. https://doi.org/10.1093/asj/sjaa421
Cotofana S, Alfertshofer M, Frank K et al (2020) Relationship between vertical glabellar lines and the supratrochlear and supraorbital arteries. Aesthet Surg J 40(12):1341–1348. https://doi.org/10.1093/asj/sjaa138
Choi DY, Bae JH, Youn KH et al (2018) Topography of the dorsal nasal artery and its clinical implications for augmentation of the dorsum of the nose. J Cosmet Dermatol 17(4):637–642. https://doi.org/10.1111/jocd.12720
Alfertshofer MG, Frank K, Ehrl D et al (2021) The layered anatomy of the nose: an ultrasound-based investigation. Aesthet Surg J. https://doi.org/10.1093/asj/sjab310
Tansatit T, Apinuntrum P, Phetudom T (2017) Facing the worst risk: confronting the dorsal nasal artery, implication for non-surgical procedures of nasal augmentation. Aesthet Plast Surg 41(1):191–198. https://doi.org/10.1007/s00266-016-0756-0
Isaac J, Walker L, Ali SR, Whitaker IS (2022) An illustrated anatomical approach to reducing vascular risk during facial soft tissue filler administration – a review. JPRAS Open. https://doi.org/10.1016/j.jpra.2022.09.006
Cotofana S, Gaete A, Hernandez CA et al (2020) The six different injection techniques for the temple relevant for soft tissue filler augmentation procedures - Clinical anatomy and danger zones. J Cosmet Dermatol 19(7):1570–1579. https://doi.org/10.1111/jocd.13491
O’Brien JX, Ashton MW, Rozen WM, Ross R, Mendelson BC (2013) New perspectives on the surgical anatomy and nomenclature of the temporal region: literature review and dissection study. Plast Reconstr Surg 131(3):510–522. https://doi.org/10.1097/PRS.0b013e31827c6ed6
Nikolis A, Enright KM, Troupis T et al (2022) Topography of the deep temporal arteries and implications for performing safe aesthetic injections. J Cosmet Dermatol 21(2):608–614. https://doi.org/10.1111/jocd.14672
Hayreh SS, Weingeist TA (1980) Experimental occlusion of the central artery of the retina. IV: Retinal tolerance time to acute ischaemia. Br J Ophthalmol 64(11):818–825. https://doi.org/10.1136/bjo.64.11.818
Mac Grory B, Lavin P, Kirshner H, Schrag M (2020) Thrombolytic therapy for acute central retinal artery occlusion. Stroke 51(2):687–695. https://doi.org/10.1161/STROKEAHA.119.027478
Schrag M, Youn T, Schindler J, Kirshner H, Greer D (2015) Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis. JAMA Neurol 72(10):1148–1154. https://doi.org/10.1001/jamaneurol.2015.1578
Rudkin AK, Lee AW, Aldrich E, Miller NR, Chen CS (2010) Clinical characteristics and outcome of current standard management of central retinal artery occlusion. Clin Exp Ophthalmol 38(5):496–501. https://doi.org/10.1111/j.1442-9071.2010.02280.x
Fiess A, Cal O, Kehrein S, Halstenberg S, Frisch I, Steinhorst UH (2014) Anterior chamber paracentesis after central retinal artery occlusion: A tenable therapy? BMC Ophthalmol 14:28. https://doi.org/10.1186/1471-2415-14-28
Murray G, Convery C, Walker L, Davies E (2021) Guideline for the management of hyaluronic acid filler-induced vascular occlusion. J Clin Aesthet Dermatol 14(5):E61–E69
Galadari H, Krompouzos G, Kassir M et al (2020) Complication of soft tissue fillers: prevention and management review. J Drugs Dermatol 19(9):829–832
Jones DH, Fitzgerald R, Cox SE et al (2021) Preventing and treating adverse events of injectable fillers: evidence-based recommendations from the American society for dermatologic surgery multidisciplinary task force. Dermatol Surg 47(2):214–226. https://doi.org/10.1097/DSS.0000000000002921
Nayfeh T, Shah S, Malandris K et al (2021) A systematic review supporting the American society for dermatologic surgery guidelines on the prevention and treatment of adverse events of injectable fillers. Dermatol Surg 47(2):227–234. https://doi.org/10.1097/DSS.0000000000002911
Khan TT, Colon-Acevedo B, Mettu P, DeLorenzi C, Woodward JA (2017) An anatomical analysis of the supratrochlear artery: considerations in facial filler injections and preventing vision loss. Aesthet Surg J 37(2):203–208. https://doi.org/10.1093/asj/sjw132
Pallua N, Grasys J, Kim BS (2018) Enhancement of progenitor cells by two-step centrifugation of emulsified lipoaspirates. Plast Reconstr Surg 142(1):99–109. https://doi.org/10.1097/PRS.0000000000004495
Pavicic T, Webb KL, Frank K, Gotkin RH, Tamura B, Cotofana S (2019) Arterial wall penetration forces in needles versus cannulas. Plast Reconstr Surg 143(3):504e–512e. https://doi.org/10.1097/PRS.0000000000005321
Alam M, Kakar R, Dover JS et al (2021) Rates of vascular occlusion associated with using needles versus cannulas for filler injection. JAMA Dermatol 157(2):174–180. https://doi.org/10.1001/jamadermatol.2020.5102
Schiraldi L, Sapino G, Meuli J et al (2022) Facial fat grafting (FFG): Worth the risk? A systematic review of complications and critical appraisal. J Clin Med 11(16):4708. https://doi.org/10.3390/jcm11164708
Vasconcelos-Berg R, Izidoro JF, Wenz F, Muller A, Navarini AA, Sigrist RMS (2023) Doppler ultrasound guided filler injections: useful tips to integrate ultrasound in the daily practice. Aesthet Surg J. https://doi.org/10.1093/asj/sjac353
Cotofana S, Schelke LW, Velthuis PJ (2023) Commentary on: doppler ultrasound guided filler injections: useful tips to integrate ultrasound in the daily practice. Aesthet Surg J. https://doi.org/10.1093/asj/sjad022
Yoon S, Kim YA (2020) Cosmetic surgery and self-esteem in South Korea: a systematic review and meta-analysis. Aesthetic Plast Surg 44(1):229–238. https://doi.org/10.1007/s00266-019-01515-1
Hong SE, Hong MK, Park BY, Woo KJ, Kang SR (2018) Is the “ghost surgery” the subject of legal punishment in Korea? Ann Surg Treat Res 94(4):167–173. https://doi.org/10.4174/astr.2018.94.4.167
Moellhoff N, Arnez T, Athanasopoulos E et al (2022) ESPRAS survey on continuing education in plastic, reconstructive and aesthetic surgery in Europe. Handchir Mikrochir Plast Chir 54(4):365–373. https://doi.org/10.1055/a-1894-7436
Giunta RE, Costa H, Demirdover C et al (2022) ESPRAS position paper on patient protection in plastic, reconstructive and aesthetic surgery. Handchir Mikrochir Plast Chir 54(4):374–376. https://doi.org/10.1055/a-1885-6162
Funding
Open Access funding enabled and organized by Projekt DEAL. BSK is funded by the German Research Foundation (DFG, KI 1973/2-1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The other authors declare that they have no conflict of interest to disclose. The authors declared no potential conflict of interest with respect to the research, authorship, and publication of this article.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed Consent
For this type of study, informed consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Moellhoff, N., Kuhlmann, C., Frank, K. et al. Arterial Embolism After Facial Fat Grafting: A Systematic Literature Review. Aesth Plast Surg 47, 2771–2787 (2023). https://doi.org/10.1007/s00266-023-03511-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00266-023-03511-y